Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Operating Expenses (2016 - 2025)

Heron Therapeutics' Other Operating Expenses history spans 12 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 10.64% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $49.1 million, up 4.2%, while the annual FY2025 figure was $49.1 million, 4.2% up from the prior year.
  • Other Operating Expenses reached $12.2 million in Q4 2025 per HRTX's latest filing, down from $12.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $39.1 million in Q2 2022 to a low of $11.0 million in Q3 2024.
  • Average Other Operating Expenses over 5 years is $20.4 million, with a median of $15.7 million recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: soared 85.71% in 2021, then crashed 49.83% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at $35.4 million in 2021, then plummeted by 49.83% to $17.8 million in 2022, then plummeted by 30.64% to $12.3 million in 2023, then fell by 10.31% to $11.1 million in 2024, then rose by 10.64% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Other Operating Expenses are $12.2 million (Q4 2025), $12.9 million (Q3 2025), and $11.6 million (Q2 2025).